Upregulation of HER-2/neu by Ovarian Ablation: Results of a Randomized Trial Comparing Leuprorelin to CMF as Adjuvant Therapy in Node-positive Breast Cancer Patients

Author： Lüftner D.  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.80, Iss.3, 2003-08, pp. : 245-255

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer

By Konecny G.  

Breast Cancer Research and Treatment, Vol. 69, Iss. 1, 2001-09 ,pp. : 53-63

Springer Publishing Company

Access to resources Recommend Favorite

Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer

By Disis M.L.   Knutson K.L.   Schiffman K.   Rinn K.   McNeel D.G.  

Breast Cancer Research and Treatment, Vol. 62, Iss. 3, 2000-08 ,pp. : 245-252

Springer Publishing Company

Access to resources Recommend Favorite

DBCG trial 89B comparing adjuvant CMF and ovarian ablation: Similar outcome for eligible but non-enrolled and randomized breast cancer patients

By Ejlertsen Bent   Jensen Maj-Britt   Mouridsen Henning   Andersen Jørn   Cold Søren   Jakobsen Erik   Kamby Claus   Sørensen Peter   Ewertz Marianne  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 709-717

Informa Healthcare

Access to resources Recommend Favorite

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

By Amadori Dino   Silvestrini Rosella   Lena Mario   Boccardo Francesco   Rocca Andrea   Scarpi Emanuela   Schittulli Francesco   Brandi Mario   Maltoni Roberta   Serra Patrizia   Ponzone Riccardo   Biglia Nicoletta   Gianni Lorenzo   Tienghi Amelia   Valerio Maria   Bonginelli Paola   Amaducci Laura   Faedi Marina   Baldini Editta   Paradiso Angelo  

Breast Cancer Research and Treatment, Vol. 125, Iss. 3, 2011-02 ,pp. : 775-784

Springer Publishing Company

Access to resources Recommend Favorite

Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/ neu in Patients with Breast Cancer

By Taucher Susanne  

Breast Cancer Research and Treatment, Vol. 82, Iss. 3, 2003-01 ,pp. : 207-213

Springer Publishing Company

Access to resources Recommend Favorite